ArticleAntibiotics (Basel, Switzerland)2022
Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection.
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Vancomycin and phage COP-80B combination therapy for Staphylococcus epidermidis periprosthetic joint infections: a preclinical mouse study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Review
- Methicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment.Nature reviews. Microbiology · 2026Review
- Phage therapy in revision arthroplasty: State of the art and application protocols.Arthroplasty (London, England) · 2026Review
- Phage Therapy: Application and Related Problems-A Review.Life (Basel, Switzerland) · 2025Review
- A TAT Peptide-Functionalized Liposome Delivery Phage System (TAT-Lip@PHM) for an Enhanced Eradication of Intracellular MRSA.Pharmaceutics · 2025Article
- The landscape of biofilm models for phage therapy: mimicking biofilms in diabetic foot ulcers using 3D models.Frontiers in microbiology · 2025Review
- Phage diversity in One Health.Essays in biochemistry · 2024Review
- Prevention and Modern Strategies for Managing Methicillin-Resistant Staphylococcal Infections in Prosthetic Joint Infections (PJIs).Antibiotics (Basel, Switzerland) · 2024Review
- Mycobacteriophages and Their Applications.Antibiotics (Basel, Switzerland) · 2024Review
- Fighting fire with fire: using infectious agents to treat persistent infection.Future microbiology · 2024Review
- Phage therapy in prosthetic joint infections caused by Staphylococcus aureus - A literature review.European journal of microbiology & immunology · 2024Review
- Biological characterization and genomic analysis of a novel methicillin-resistantMicrobiology spectrum · 2024Article
- Improving phage therapy by evasion of phage resistance mechanisms.JAC-antimicrobial resistance · 2024Review
- Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University.Scientific reports · 2024Article
- Phage Therapy Against Antibiotic-Resistant and Multidrug-Resistant Infections Involving Nonhealing Wounds and Prosthetic Joint Infections Associated With Biofilms: A Mini-Review.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Review
- Bacteriophage therapy for drug-resistantFrontiers in cellular and infection microbiology · 2024Review
- Bacteriophage-mediated approaches for biofilm control.Frontiers in cellular and infection microbiology · 2024Review
- Phage Therapy as an Alternative Treatment Modality for ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Isolation andFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prosthetic joint infections are a devastating complication of joint replacement surgery. Consequently, novel therapeutics are needed to thwart the significant morbidity and enormous financial ramifications that are associated with conventional treatments. One such promising adjuvant therapeutic is bacteriophage therapy given its antibiofilm activity and its ability to self-replicate. Herein we discuss the case of a 70-year-old female who had a recalcitrant MRSA prosthetic knee and femoral lateral plate infection who was successfully treated with adjuvant bacteriophage therapy. Moreover, this case discusses the importance of propagating bacteriophage therapeutics on bacteria that are devoid of toxins and the need to ensure bacteriophage activity to all bacterial morphologies. Overall, this case reinforces the potential benefit of using personalized bacteriophage therapy for recalcitrant prosthetic joint infections, but more translational research is needed to thereby devise effective, reproducible clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.